GlucoTrack, Inc. Common Stock (GCTK) is a publicly traded Healthcare sector company. As of May 21, 2026, GCTK trades at $0.47 with a market cap of $1.77M and a P/E ratio of 0.01. GCTK moved -13.39% today. Year to date, GCTK is -87.99%; over the trailing twelve months it is -94.71%. Its 52-week range spans $0.44 to $2,970.00. Rallies surfaces GCTK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Glucotrack Submits IDE for 3-Year Lifespan Implantable Glucose Monitor Study: Glucotrack submitted its Investigational Device Exemption application to the FDA on May 7 to launch a U.S. clinical study of its fully implantable continuous blood glucose monitoring system. The sensor is designed for up to three years of use without external wearables or frequent calibration.
| Metric | Value |
|---|---|
| Price | $0.47 |
| Market Cap | $1.77M |
| P/E Ratio | 0.01 |
| EPS | $31.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $2,970.00 |
| 52-Week Low | $0.44 |
| Volume | 15.42K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-19.39M |
| Gross Margin | 0.00% |
GCTK analyst coverage data. Average price target: $0.00.